Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight.

Trial Profile

Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs NNC 0174 0833 (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 13 Oct 2017 Planned primary completion date changed from 7 Dec 2017 to 24 Jan 2018.
    • 13 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 26 Sep 2017 Planned number of patients changed from 84 to 96.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top